AU2015256331B2 - Formulations of Cyclophosphamide liquid concentrate - Google Patents

Formulations of Cyclophosphamide liquid concentrate Download PDF

Info

Publication number
AU2015256331B2
AU2015256331B2 AU2015256331A AU2015256331A AU2015256331B2 AU 2015256331 B2 AU2015256331 B2 AU 2015256331B2 AU 2015256331 A AU2015256331 A AU 2015256331A AU 2015256331 A AU2015256331 A AU 2015256331A AU 2015256331 B2 AU2015256331 B2 AU 2015256331B2
Authority
AU
Australia
Prior art keywords
cyclophosphamide
aqueous liquid
liquid composition
substantially non
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015256331A
Other languages
English (en)
Other versions
AU2015256331A1 (en
Inventor
Philip Christopher Buxton
Nagesh R. Palepu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auromedics Pharma LLC
Original Assignee
Auromedics Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54366856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015256331(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auromedics Pharma LLC filed Critical Auromedics Pharma LLC
Publication of AU2015256331A1 publication Critical patent/AU2015256331A1/en
Application granted granted Critical
Publication of AU2015256331B2 publication Critical patent/AU2015256331B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015256331A 2014-05-09 2015-05-01 Formulations of Cyclophosphamide liquid concentrate Ceased AU2015256331B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461991247P 2014-05-09 2014-05-09
US61/991,247 2014-05-09
PCT/US2015/028862 WO2015171460A2 (en) 2014-05-09 2015-05-01 Formulations of cyclophosphamide liquid concentrate

Publications (2)

Publication Number Publication Date
AU2015256331A1 AU2015256331A1 (en) 2016-11-17
AU2015256331B2 true AU2015256331B2 (en) 2020-03-12

Family

ID=54366856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015256331A Ceased AU2015256331B2 (en) 2014-05-09 2015-05-01 Formulations of Cyclophosphamide liquid concentrate

Country Status (10)

Country Link
US (3) US9662342B2 (enExample)
EP (1) EP3139929A4 (enExample)
JP (1) JP6516831B2 (enExample)
KR (1) KR20170008252A (enExample)
CN (1) CN106456654A (enExample)
AU (1) AU2015256331B2 (enExample)
BR (1) BR112016026140A2 (enExample)
CA (1) CA2948148C (enExample)
RU (1) RU2016147362A (enExample)
WO (1) WO2015171460A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
WO2016132270A1 (en) 2015-02-16 2016-08-25 Leiutis Pharmaceuticals Pvt Ltd Stable ready to use cyclophosphamide liquid formulations
US12453737B2 (en) 2018-08-03 2025-10-28 Sinotherapeutics Inc. Method for hydrating lyophilized cyclophosphamide composition and product thereof
WO2020178725A1 (en) * 2019-03-04 2020-09-10 Alembic Pharmaceuticals Limited Stable liquid composition of cyclophosphamide
BR112022000204A2 (pt) 2019-07-10 2022-02-22 Intas Pharmaceuticals Ltd Composição oral estável de ciclofosfamida, pó estável para solução oral, pó estável para solução oral na forma de um kit, e processo para preparação de um kit
WO2021009595A1 (en) * 2019-07-15 2021-01-21 Hetero Healthcare Limited Cyclophosphamide injectable composition and methods for producing same
US20230310468A1 (en) * 2020-08-17 2023-10-05 Sandoz Ag Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids
WO2023059885A1 (en) 2021-10-08 2023-04-13 Slayback Pharma Llc, Stable pharmaceutical compositions of cyclophosphamide
US11642358B1 (en) 2022-02-14 2023-05-09 Extrovis Ag Stable pharmaceutical formulation
US20240180935A1 (en) * 2022-11-22 2024-06-06 Navinta, Llc Solution formulation of cyclophosphamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
WO2002002125A1 (en) * 2000-06-30 2002-01-10 Dbl Australia Pty Ltd Injectable composition
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
WO2014068585A1 (en) * 2012-10-29 2014-05-08 Leiutis Pharmaceuticals Pvt. Ltd. Novel lyophilized compositions of cyclophosphamide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR75178E (enExample) 1956-12-20 1961-09-08
ES2038623T3 (es) * 1986-07-11 1993-08-01 Asta Medica Aktiengesellschaft Procedimiento para preparar soluciones de oxazafosforinas con estabilidad mejorada.
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
ATE348621T1 (de) * 1997-10-13 2007-01-15 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
CN1923280A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含双氯乙胺类药物的抗癌缓释注射剂
JP5318403B2 (ja) * 2007-11-30 2013-10-16 株式会社Ｓｏｋｕｄｏ 基板処理装置
US8278220B2 (en) * 2008-08-08 2012-10-02 Fei Company Method to direct pattern metals on a substrate
EP2442789A1 (en) * 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
WO2002002125A1 (en) * 2000-06-30 2002-01-10 Dbl Australia Pty Ltd Injectable composition
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
WO2014068585A1 (en) * 2012-10-29 2014-05-08 Leiutis Pharmaceuticals Pvt. Ltd. Novel lyophilized compositions of cyclophosphamide

Also Published As

Publication number Publication date
RU2016147362A (ru) 2018-06-13
US9662342B2 (en) 2017-05-30
WO2015171460A3 (en) 2016-04-21
RU2016147362A3 (enExample) 2018-10-01
JP6516831B2 (ja) 2019-05-22
KR20170008252A (ko) 2017-01-23
US20150320775A1 (en) 2015-11-12
CA2948148C (en) 2022-12-06
BR112016026140A2 (pt) 2018-08-07
CA2948148A1 (en) 2015-11-12
EP3139929A4 (en) 2018-01-03
US20170232015A1 (en) 2017-08-17
US20150320774A1 (en) 2015-11-12
AU2015256331A1 (en) 2016-11-17
CN106456654A (zh) 2017-02-22
EP3139929A2 (en) 2017-03-15
JP2017514924A (ja) 2017-06-08
WO2015171460A2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
AU2015256331B2 (en) Formulations of Cyclophosphamide liquid concentrate
US7985757B2 (en) Argatroban formulation
JP2018109005A (ja) ベンダムスチン製剤
RS55491B2 (sr) Formulacije bendamustina
US20220047509A1 (en) Stabilized liquid formulation of levothyroxine
WO2016001905A2 (en) Stable liquid ready-to-use injectable formulation of bortezomib
CN108601730B (zh) 万古霉素的制剂
US20180311203A1 (en) Liquid formulation of cabazitaxel
US11058745B1 (en) Stable liquid pharmaceutical compositions of daptomycin
CN116367822A (zh) 植物甲萘醌组合物
HK1233162A1 (en) Formulations of cyclophosphamide liquid concentrate
WO2016079749A2 (en) Process for preparation of parenteral formulation of anidulafungin
CA2762321A1 (en) Fosphenytoin composition
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
EP4622649A1 (en) Novel solution formulation of cyclophosphamide
EP2934524B1 (en) Penethamate veterinary injectable formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired